

**“ANALYSIS OF MATABOLITES OF ADRENERGIC
BRONCHODILATORS AND ITS APPLICATION TO IN VITRO
METABOLISM BY LC-MS”**

Allabaksha M.Shaikh,¹Rukhsana M.Pinjari,² Sayyed Mateen Moin³

MrunalK.Shirsat,⁴I.J.Singhvi⁵

1. Allana College of Pharmacy 2390/B.K.B Hidayatullah Road, Pune-411001
2. AAEMFs Delight College of Pharmacy, Koregaon BhimaTah- Shirur, Dist-Pune
3. Oriental College of Pharmacy, Sanpada, Navi-Mumbai-400705
4. SBSPMs, B-Pharmacy College of Pharmacy Ambejogai-431517
5. Nootan Pharmacy College, Sankalchand Patel University, Visnagar

ABSTRACT

A UPLC-MS method for the quantification of the levalbuterol is described, in addition to its application to the in vitro study of metabolism in rat liver microsomes. Protein precipitation extraction was used to extract the sample from microsomes and the separation was performed on a C18 protected with a guard column of the same type using Water: Acetonitrile with 0.1% Formic acid as the mobile phase, at a flow rate of 0.3 ml min⁻¹. The detection was carried out at 276 nm. The method proved to be linear in the range of 2.5-30 ng ml⁻¹, with quantification Precision and accuracy, demonstrated by within-day and between-day assays, were lower than 15%. The metabolic study demonstrated that metabolism found two metabolites formed in the incubation mixture of liver microsomes and sample with NADPH, which are identified by LC-MS.

Keywords: In vitro metabolism, LC-MS, liver microsomes, levalbuterol

Correspondence Author: - Rukhsana M.Pinjari

AAEMFs Delight College of Pharmacy, Koregaon BhimaTah- Shirur, Dist-Pune

INTRODUCTION

Methods of measuring drugs in biological media are becoming increasingly important for the study of bioavailability & bioequivalence studies, quantitative evaluation of drugs and their metabolites, new drug development, clinical pharmacokinetics, research in basic biomedical and pharmaceutical sciences and therapeutic drug monitoring. Levalbuterol fig.1 (a), chemically 2-(Hydroxymethyl)-4-[(1*S*) 1-hydroxy-2-(tert-butylamino) ethyl] phenol is a single isomer beta2-agonist that differs from racemic albuterol by elimination of (*S*)-Albuterol. Levalbuterol leads to activation of beta2-adrenergic receptors on airways smooth muscle leading to the activation of adenylate cyclase, which increases the intracellular concentration of cAMP. The increase in cAMP is associated with the activation of protein kinase a which in turn, inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation and bronchodilator. Levalbuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cAMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways¹⁻⁴. (*R*)-Salbutamol i.e. levalbuterol is metabolized up to 12 times faster than (*S*)-salbutamol.




Fig. 1: Chemical structure of (a) Levalbuterol and (b) Albuterol

Literature survey revealed that there is no any UPLC method for levalbuterol⁵⁻⁹. For the estimation of the drugs present in the biological fluid, UPLC method is considered to be more suitable since this is a powerful and rugged method. It is also extremely specific, accurate, sensitive and rapid. In this study we have done a metabolite study by using liver microsomes, with a protein precipitation extraction and improved sensitivity for the determination of Levalbuterol in plasma and the developed method is validated as per regulatory requirements.

MATERIALS AND METHODS

Chemicals

Levalbuterol was gifted by FDC Ltd. Mumbai. UPLC grade solvents (Acetonitrile, Methanol) were obtained from Merck and milli-Q water was from SG Series Compact Pretreatment Module.

Instrument

The Waters Acquity UPLC system equipped with a MS detector and an auto sampler was used. Chromatographic separations were performed using the acquity UPLC BEH C-18, 1.7 μ m 2.1 x 100mm column and analyzed by LC software Turbochrome work station.

Preparation of solutions

50mM ammonium bicarbonate buffer was prepared by dissolving approximately 1.96 gm of ammonium bicarbonate in 500 ml of water and the pH was adjusted to 7.8 with acetic acid.

Preparation of standard

Levalbuterol and Doxophylline stock solutions were prepared with a concentration of 1 mg/ml by dissolving in methanol and the stock solutions were stored in the refrigerator. Spiking solutions of Levalbuterol for the preparation of calibration standards and quality control samples were prepared in methanol and spiked in to the plasma at the ratio of 1:8. The calibration curve was generated using seven calibration standards with the concentrations of 2.5 μ g/ml (STD 1), 5 μ g/ml (STD 2), 10 μ g/ml (STD 3), 15 μ g/ml (STD 4), 20 μ g/ml (STD 5), 25 μ g/ml (STD 6) and 30 μ g/ml (STD 7). The Quality Control samples were prepared with the concentrations of 5 μ g/ml (LQC), 15 μ g/ml (MQC) and 25 μ g/ml (HQC). The bulk spiked calibration standards and quality control samples were stored in the freezer.

Sample preparation and extraction

Levalbuterol from the plasma was extracted by using protein precipitation extraction technique. Blood samples were collected in heparinised tubes and immediately placed on ice and taken to the lab where they were centrifuged at 5000rpm for 5 min at room temperature. The resulting plasma samples were stored at -75°C until analysis. Aliquot 160 μ l of plasma into eppendorf tubes and added 20 μ l of internal standard dilution and vortexes to mix the contents. 20 μ l of above sample is added and Levalbuterol is extracted by using methanol as a precipitating solvent

and vortexed for 30sec. Then the extract was centrifuged at 4⁰c, 7000rpm for 10 min. The supernatant was taken and transferred to HPLC vials¹⁰

Preparation of Stock Solution for Metabolite Study


4.551mg drug 10ml (1.5mM)

UPLC method

The mobile phase used was water (phase A) and acetonitrile (Phase B). Before analysis, the mobile phase was filtered through 0.45 µm filter paper and then degassed ultrasonically for 15 min. A gradient method was developed table 1. For analysis the mobile phase was initially composed of 90% solvent-A and held for 1 min. The mobile phase composition was then linearly programmed to 90% solvent-B in 20 min and held for 1 min. The mobile phase condition was returned to the starting solvent mixture in 1 min. The analysis was conducted at a flow rate of ml/min. The eluent was monitored at a wavelength of 276nm. The total run time was 20 min and injection volume was 5µl. Here Capillary Voltage was 2.97 kV, Cone Voltage was 37 V, Extractor voltage was 2 kV, RF lens voltage was 0.1kV, Source temperature was 120⁰C, Desolvation temp was 413⁰C, Desolvation flow rate was 700L/hr and Cone flow rate was 25L/hr¹¹.

Table: LC-MS method for metabolite

Time (min)	%A	%B
0	90	10
6	90	10
9	40	60
16	40	65
19	10	90
20	10	90



LC-MS spectra of Levalbuterol in Full Scan mode

In Vitro Metabolism

- Sacrifice animals by cervical dislocation, decapitation, or CO₂ asphyxiation.
- Remove the liver rapidly and place in ice-cold homogenizing buffer in an ice bath.
- Perfuse the liver by inserting a 10-ml syringe and injecting buffer until the effluent is clear and colorless (10 ml buffer for a rat liver).
- Remove excess moisture by blotting on paper towels and weigh the tissue.
- Add 3 vol of ice-cold homogenizing buffer and mince the liver into small pieces with surgical scissors.
- Homogenize, on ice, using a motor-driven Teflon pestle (Potter type) with 10 strokes.
- Place homogenate into an ice-cold labeled 1.5-ml centrifuge tube.

Isolation of Microsomes

- Centrifuge the homogenate 15 min at 12,500 × g, 4°C. The supernatant is the S9 homogenate fraction.

- Carefully decant the supernatant into a 1.5-ml ultracentrifuge tube and discard the pellet. Balance pairs of tubes to within 0.01 g using ice-cold homogenizing buffer, pH 7.4
- Ultracentrifuge the supernatant 70 min at $105,000 \times g$, 4°C .
- Decant the supernatant and resuspend the pellet in 8ml ice-cold pyrophosphate buffer. Homogenize the pellet using the hand-held blender for 3 to 5 sec.
- Rebalance the tubes and ultracentrifuge 45 min at $105,000 \times g$, 4°C .
- Decant the supernatant, add 6 ml ice-cold microsome buffer and resuspend the pellet with a hand-held blender. Further homogenize the pellet with the Potter-type teflon pestle and transfer into a clean tube. Wash the teflon pestle with 2 ml ice-cold microsome buffer and combine.
- Determine the protein concentration of a small aliquot by standard methods. Adjust to the desired protein concentration (usually 10 to 20 mg/ml) with microsome buffer. Dispense 0.5-ml aliquots into labeled tubes and store at -70° to -80°C .

Methodology for the Determination of Metabolites in Liver Microsomes

Incubation of Levalbuterol with rat liver microsomes was carried out at 37°C in a shaking incubator. The incubation solution contained 0.5 ml 100 mM potassium phosphate buffer (pH 7.4), 1mg protein/ml microsomes, 2 mM NADPH and 1.5 mM levalbuterol in a final volume of 100 μl . The enzyme reaction was initiated by adding NADPH after an initial 10-min preincubation. The reaction was terminated by adding 1 ml of cold methanol. The solution was vortex-mixed and centrifuged at 4°C for 10 min at 3750 rpm. The supernatant was transferred to an epindorff tube and dried under a stream of nitrogen at room temperature. The residue was reconstituted in 200 μl of methanol. Metabolites formed are determined by LC/MS¹²⁻¹⁴.

In Vitro Metabolism of Drug in Rat Liver Microsomes

1mg protein/ml (Liver Microsomes)

ml 100mM Potassium Phosphate Buffer (pH


7.4) 1.5mM Levalbuterol Solution

2mM NADPH


Incubate in Shaking Incubator for 2Hr

Stop Incubation Reaction with MeOH

Centrifuge, Collect Supernatant & Inject in HPLC & LC-MS



Mass spectrum of levalbuterol





Representative Chromatogram of metabolites in liver microsomes by LC-MS

Name	Levalbuterol	M1	M2
RT (min.)	1.1	1.87	3.09


RESULT AND DISCUSSION**First metabolite (M₁):**

This metabolite obtained after deamination showed a molecular ion at m/z 167. The peak eluting yielded a molecular ion at M+1,168.

**Chromatogram of first metabolites in liver microsomes by LC-MS**




4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol




Second metabolite (M₂)

This metabolite peak yielded a protonated molecular ion at m/z 221 and ESI mass of this metabolite obtained after dehydration showed a molecular ion at M+1, 222.



Chromatogram of second metabolites in liver microsomes by LC-MS



CONCLUSION

- ☒ The method described here for the quantitation of Levalbuterol in rat plasma is a simple, specific, rapid, accurate and stable LC-MS assay. The method is found to be highly precise and suitable for *in vitro* metabolite study in rat liver microsomes.
- ☒ *In vitro* metabolism study for levalbuterol has been conducted in which two metabolites were detected by HPLC and identified by LC-MS.

REFERENCES

1. Zhoua S., Song Q., Tangb Y., Naidong W., Critical Review of Development, Validation and Transfer of Bioanalytical LC-MS/MS Methods, *CurrentPh. Anal.*, Bentham Science Publishers, **1(1)**, 2005, 3-14.
2. Gerry C., Chromatography-Principles and Theory, Analytical Chemistry, John Wiley Publishers, New Delhi, sixth ed., 2007, 556-571.
3. Guzzetta A., Reverse Phase HPLC Basics for LC/MS, An Ion Source Tutorial, twenty second ed., 2001, Available from URL:
<http://www.ionsource.com/tutorial/chromatography/rphplc.htm>
4. Yinon J., Advances in Forensic Applications of Mass Spectrometry, Ch 6, Analysis of Explosives by LC/MS, CRC Press, Boca Raton FL, **3**, second ed., 1995.
5. Song M., Wang L., Zhao H., Hang T., Wen A., Yang L., Lee J., Rapid and Sensitive Liquid Chromatography–Tandem Mass Spectrometry: Assay Development,

- Validation and Application to a Human Pharmacokinetic Study, *J. Ch. B*, **875**, 2008, 515–521.
6. Kadar E.P., Gregg R.D., Kelly, Blanchard A., Palmer C., Shire T., Henry J., Yorzinski, Zhongli Z., Quantitative HPLC Tandem Mass Spectrometry (LC/MS/MS) Analysis of Low-level Impurities in Active Pharmaceutical Ingredients, Pfizer Global Research & Development. Available From URL: <http://americanpharmaceuticalreview.com>.
 7. Niessen W., Quantitative Bioanalysis and Metabolite Identification by LC-MS, *Hyphen Mass Spec*, 2006, 1-35. Available From: URL: <http://www.bioanalysis.org/slides/06505.pdf>
 8. Kostiainen R., Kotiaho T., Auriola S., Kuuranne T., Liquid Chromatography/Atmospheric Pressure Ionization–Mass Spectrometry in Drug Metabolism Studies, *J. Mass Spectrom.*, **38(4)**,2003, 357–372.
 9. Badman E., Graham CooksR.,Mass Analyzers, *J. Mass Spectrom.*, **35(6)**, 2000, 659-671
 10. General Guidelines for Preparing Samples for MS Analysis, Available from URL: <http://massspec.cm.utexas.edu/protocols.pdf>
 11. Hoffmann E., Stroobant V., Mass Spectrometry Principle and Application, Tandem Mass Spectrometry, John Wiley Publishers, London, thirded., 2007, 189-216.
 12. Jiunn H., Anthony Y., Role of Pharmacokinetics and Metabolism in Drug Discovery and Development, *Pharmacological Review*,**49(4)**, 1997, 403-449.
 13. Sepuri A.,Maravajhala V., Role of Human Liver Microsomes in *In Vitro* Metabolism of Drugs A Review, *Appl. Biochem. Biotech.***160**, 2010, 1699-1722.
 14. Yongxin Z., Hwa C., Jean Z., Peter T., In Vitro Metabolism Study of Resveratrol and Identification and Determination of its Metabolite Piceatannol by LC/EC and LC/MSMS, *A. J. of Drug Met. And Pkts*, Hong Kong Medical Publisher, **5(1)**, 2005, 49-54.